US Stock Insider Trading | Vaxcyte Discloses 13 Insider Transactions on March 2

K-LinePoet · 2026-03-13T00:01:18+00:00

On March 2, 2026, Vaxcyte (PCVX) disclosed executive insider trading activities, including Cowan Elvia's purchase of 7,716 shares and trading transactions by multiple executives. Vaxcyte is a company focused on developing next-generation vaccines aimed at improving global health.

K-LinePoet

2026-03-13 00:01:18

Abstract generation in progress

On March 2, 2026, Vaxcyte (PCVX) disclosed 13 insider transactions. Executive Cowan Elvia purchased 7,716 shares on March 2, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 2, 2026	Executive	Wassil Jim	February 27, 2026	Buy	3,202	61.74	$197,700
March 2, 2026	Executive	GUGGENHIME ANDREW	March 2, 2026	Sell	1,907	61.98	$118,200
March 2, 2026	Executive	Cowan Elvia	March 2, 2026	Sell	569	61.98	$35,300
March 2, 2026	Executive	Cowan Elvia	February 26, 2026	Buy	7,716	25.92	$200,000
March 2, 2026	Executive	Wassil Jim	March 2, 2026	Sell	1,907	61.98	$118,200
March 2, 2026	Executive	Dhaliwal Harpreet S.	March 2, 2026	Sell	757	61.98	$46,900
March 2, 2026	Director	PICKERING GRANT	March 2, 2026	Sell	5,394	61.98	$334,300
January 2, 2025	Executive	Dhaliwal Harpreet S.	December 31, 2025	Sell	9,743	46.69	$454,900
December 29, 2025	Executive	Cowan Elvia	December 23, 2025	Sell	6,716	47.94	$321,900
December 29, 2025	Executive	Cowan Elvia	December 23, 2025	Sell	4,907	47.90	$235,000

[Company Profile]

Vaxcyte, Inc. was incorporated on November 27, 2013, in Delaware. The company is a next-generation vaccine company focused on developing novel vaccines to prevent or treat some of the most common and deadly infectious diseases worldwide. Their cell-free protein synthesis platform enables them to design and produce protein carriers and antigens, which are key components of vaccines.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.